The toxicity of doxorubicin (DOX) limits its clinical application. Nevertheless, at present, there is no effective drug to prevent DOX-induced cardiac injury. miR-204 is a newly discovered miRNA with many protective effects on cardiovascular diseases. However, little research has been done on the effects of miR-204 on DOX-induced cardiac injury. Our study is aimed at investigating the effect of miR-204 on DOX-induced myocardial injury. An adenoassociated virus system was used to achieve cardiac-specific overexpression of miR-204. Two weeks later, the mice were intraperitoneally injected with DOX (15 mg/kg) to induce cardiac injury. H9c2 myocardial cells were used to validate the role of miR-204 in vitro. Our study showed that miR-204 expres...
Doxorubicin (DOX) could trigger congestive heart failure, which largely limited the clinical use of ...
Cardiotoxicity remains a serious problem in anthracycline-treated oncologic patients. Therapeutic m...
Doxorubicin (DOX) is a broad-spectrum anti-tumor drug, but its cardiotoxicity limits its clinical ap...
Doxorubicin (DOX) is an anthracycline drug with a wide spectrum of antineoplastic activities. Howeve...
Background. The clinical usefulness of doxorubicin (DOX), an anthracycline with antitumor activity, ...
Clinical application of doxorubicin (DOX), an anthracycline antibiotic with potent anti- tumor effec...
<div><p>Anti-cancer therapy based on anthracyclines (DNA intercalating Topoisomerase II inhibitors) ...
Anti-cancer therapy based on anthracyclines (DNA intercalating Topoisomerase II inhibitors) is limit...
Copyright © 2015 Hasahya Tony et al. This is an open access article distributed under the Creative C...
Doxorubicin (DOX, an anthracycline) is a widely used chemotherapy agent against various forms of can...
An in depth investigation at the genomic level is needed to identify early human-relevant cardiotoxi...
Doxorubicin (DOX) is a chemotherapeutic drug limited in its usefulness by an adverse side effect, ca...
Doxorubicin (DOX, an anthracycline) is a widely used chemotherapy agent against various forms of can...
Doxorubicin (DOX, an anthracycline) is a widely used chemotherapy agent against various forms of can...
Anti-cancer therapy based on anthracyclines (DNA intercalating Topoisomerase II inhibitors) is limit...
Doxorubicin (DOX) could trigger congestive heart failure, which largely limited the clinical use of ...
Cardiotoxicity remains a serious problem in anthracycline-treated oncologic patients. Therapeutic m...
Doxorubicin (DOX) is a broad-spectrum anti-tumor drug, but its cardiotoxicity limits its clinical ap...
Doxorubicin (DOX) is an anthracycline drug with a wide spectrum of antineoplastic activities. Howeve...
Background. The clinical usefulness of doxorubicin (DOX), an anthracycline with antitumor activity, ...
Clinical application of doxorubicin (DOX), an anthracycline antibiotic with potent anti- tumor effec...
<div><p>Anti-cancer therapy based on anthracyclines (DNA intercalating Topoisomerase II inhibitors) ...
Anti-cancer therapy based on anthracyclines (DNA intercalating Topoisomerase II inhibitors) is limit...
Copyright © 2015 Hasahya Tony et al. This is an open access article distributed under the Creative C...
Doxorubicin (DOX, an anthracycline) is a widely used chemotherapy agent against various forms of can...
An in depth investigation at the genomic level is needed to identify early human-relevant cardiotoxi...
Doxorubicin (DOX) is a chemotherapeutic drug limited in its usefulness by an adverse side effect, ca...
Doxorubicin (DOX, an anthracycline) is a widely used chemotherapy agent against various forms of can...
Doxorubicin (DOX, an anthracycline) is a widely used chemotherapy agent against various forms of can...
Anti-cancer therapy based on anthracyclines (DNA intercalating Topoisomerase II inhibitors) is limit...
Doxorubicin (DOX) could trigger congestive heart failure, which largely limited the clinical use of ...
Cardiotoxicity remains a serious problem in anthracycline-treated oncologic patients. Therapeutic m...
Doxorubicin (DOX) is a broad-spectrum anti-tumor drug, but its cardiotoxicity limits its clinical ap...